MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...

Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with ...
The Manila Times

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...

The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and significant responses were observed across key secondary endpoints, including ACR20 ...

monday.com Ltd. (MNDY) Q2 2026 Earnings Call Transcript

Q2 2026 Earnings Call August 10, 2026 8:30 AM EDTCompany ParticipantsByron Stephen - Director of Investor RelationsRoy Mann ...

Medical Properties Trust, Inc. (MPT) Q2 2026 Earnings Call Transcript

Medical Properties Trust, Inc. ( MPT) Q2 2026 Earnings Call August 10, 2026 11:00 AM EDT Hello, everyone. Thank you for joining us, and welcome to Medical Properties Trust Second Quarter 2026 Earnings ...

BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates

Commercial Updates: The second quarter total revenues, net totaled $243.7 million, comprised of $222.4 million of U.S. Attruby net product revenue, $15.4 million from royalty revenue, and $5.8 million ...